Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
241 participants
OBSERVATIONAL
2024-10-30
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the study is to analyze the clinical features and survival of patients who received a PTLD diagnosis with the target to assess a survival outcome, to obtain an epidemiologic and clinical characterization of the subpopulations affected by PTLD, to recognize unfavorable properties, to report the current treatment strategies, to provide rationale for the design of a prospective registry in order to develop future novel treatments.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study in Patients Who Underwent an Haploidentical Transplantation With T-repleted Bone Marrow
NCT02049424
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
NCT02338479
aCGH Impacts Survival in Plasma Cell PTLD
NCT02984215
HLH Patients - a Retrospective Study
NCT05531721
National Marrow Donor Program Long-Term Donor Follow-Up
NCT01362179
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The following clinical characteristics of the patient at the time of PTLD diagnosis and pathology will be taken into consideration: positivity of EBV virus, serum LDH concentration, PTLD subtype (early lesion, polymorphic or monomorphic PTLD), lymphoma histotype, stage of disease according to the Ann Arbor classification and localization (nodal or extranodal), immunosuppressive regimen taken by the patient since the transplant, therapeutic approach adopted, and response obtained.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with histological diagnosis of PTLD
patients with histological diagnosis obtained from a biopsy sample in 10 years' time frame (from 01/01/2011 to 31/12/2021) of PTLD (from allogeneic transplantation (both SOT and HSCT))
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age over 18 years at time of diagnosis of PTLD;
* previously subjected to allogeneic transplantation (both SOT and HSCT);
* diagnosis of PTLD obtained in 10 years' time frame (from 01/01/2011 to 31/12/2021);
* free and voluntary written informed consent (included unreachable subjects according to Art. 36 UE Regulation 2016/679 and to the current Italian Privacy Regulation).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pierre Fabre Pharma AG
INDUSTRY
Fondazione Italiana Linfomi - ETS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Federica Cavallo, MD
Role: PRINCIPAL_INVESTIGATOR
Ematologia Universitaria - A.O.U. Citta della Salute e della Scienza di Torino
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Ematologia
Milan, MI, Italy
Centro Di Riferimento Oncologico Di Aviano, S.O.C. Oncologia Medica e dei Tumori Immunocorrelati
Aviano, , Italy
Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
Bergamo, , Italy
A.O. UNIVERSITARIA POLICLINICO S.ORSOLA-MALPIGHI DI BOLOGNA - Istituto di Ematologia "Seragnoli"
Bologna, , Italy
A.O. Spedali Civili di Brescia - Ematologia
Brescia, , Italy
Ospedale Businco - Divisione di Ematologia
Cagliari, , Italy
A.O. S. Croce e Carle - S.C. di Ematologia e Trapianto di Midollo Osseo
Cuneo, , Italy
A.O. UNIVERSITARIA CAREGGI DI FIRENZE - Unità funzionale di Ematologia
Florence, , Italy
ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia
Miano, , Italy
Istituto Scientifico San Raffaele - Unitа Linfomi - Dipartimento Oncoematologia
Milan, , Italy
AOU Maggiore della Caritа di Novara - SCDU Ematologia
Novara, , Italy
IRCCS ISTITUTO ONCOLOGICO VENETO (IOV) - Oncologia 1
Padua, , Italy
IRCCS Policlinico San Matteo - Divisione di Ematologia
Pavia, , Italy
Policlinico Universitario Campus Bio-Medico - Ematologia - Trapianto cellule staminali - Medicina Trasfusionale e Terapia cellulare
Roma, , Italy
Dipartimento di Medicina Traslazionale e di Precisione - Policlinico Umberto I - Università "La Sapienza" Istituto Ematologia
Roma, , Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica S. Cuore - Ematologia
Roma, , Italy
AOU Senese - U.O.C. Ematologia
Siena, , Italy
A.O. UNIVERSITARIA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - SC Ematologia
Torino, , Italy
A.O. Città della Salute e della Scienza - Ematologia Universitaria
Torino, , Italy
Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) - SOC Clinica Ematologica
Udine, , Italy
ULSS 8 Berica - Ospedale S. Bortolo - Ematologia
Vicenza, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FIL_PTLD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.